As a result of advances in curative therapies, more than 80% of children and adolescents diagnosed with cancer are expected to survive into adulthood (Jemal, Siegel, Xu, & Ward, 2010; Noone et al., 2017). This unique population may experience long-term physical and psychosocial sequela including chronic health conditions (CHCs), high levels of distress, poor health-related quality of life, and unmet psychosocial needs (Ness et al., 2008). Late effects of treatment may affect multiple organ systems including reproductive, endocrine, gastrointestinal, urinary tract, musculoskeletal, neurologic, auditory, ocular, oral/dental, dermatologic, cardiovascular, pulmonary, metabolic, immune systems as well as other aspects of life including psychosocial, behavioral, and neurocognitive functioning. This population is also at increased risk for subsequent malignancies (Bhakta, Liu, Ness, Baassiri, & Eissa, 2017; Oeffinger et al., 2006). The Childhood Cancer Survivor Study includes individuals who have survived 5 or more years after a diagnosis of cancer (leukemia, tumor, or similar illness) diagnosed during childhood or adolescence, and reported the cumulative incidence of CHCs in this population was 73.4% (30 years after diagnosis), with 42.4% of those conditions considered severe, disabling, or life threatening (Oeffinger et al., 2006). More recently, the St. Jude Lifetime Cohort Study (SJLIFE) reported the cumulative incidence of CHCs for 819452J POXXX10.